阿帕替尼联合其他方法治疗肿瘤的研究进展

血管新生在肿瘤的生长以及转移过程中发挥重要作用,其中血管内皮生长因子受体2(VEGFR2)是关键的调控因子。甲磺酸阿帕替尼是我国历经十年研制成功的一种小分子酪氨酸激酶抑制剂,可高特异性结合VEGFR2。目前阿帕替尼单药在临床已成功应用于晚期胃癌、非小细胞肺癌、乳腺癌等常见肿瘤的治疗。阿帕替尼与其他抗肿瘤疗法的联用往往可以达到增加药效、减少不良反应的效果。本文主要针对目前报道过的临床试验以及基础研究来简要说明阿帕替尼与其他药物联合治疗用于不同肿瘤的治疗效果以及作用机制。

Research Progress of Combination Therapy of Apatinib on Tumor

Angiogenesis plays an important role in tumor growth and metastasis, and vascular endothelial growth factor receptor 2 (VEGFR2) is a key regulatory factor in the process of angiogenesis. Apatinib mesylate is a small molecule tyrosine kinase inhibitor developed over ten years in China. At present, apatinib as single agent has been successfully used in the clinical treatment of advanced gastric cancer, non-small cell lung cancer and breast cancer, etc. The combination of apatinib and other anti-tumor therapies often increases the efficacy and reduces side effects at the same time. In this review, the therapeutic effect and mechanism of apatinib combined with other therapies for varies of tumors were briefly summarized, according to recently reported clinical cases and preclinical researches.